Previous 10 | Next 10 |
Merger activity remained unchanged last week with four new deals announced and one deal closing. Deal Statistics: New Deals: The acquisition of DryShips ( DRYS ) in a going private transaction for $915.73 million or $5.25 per share in cash. We added DRYS as a potential deal to t...
Investors trying to divine the state of the trade war with China were heartened by optimistic comments from President Trump on Monday, sending major benchmarks higher. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) both gained abou...
Amgen (NASDAQ: AMGN) CEO Bob Bradway said in the big biotech's second-quarter conference call last month that Amgen was "looking at ways to grow through business development." We now know one of those ways. On Monday morning, Amgen announced that it was buying psoriasis and psoriatic arth...
Stop! My original title for this morning's piece was Stop Selling! That's because the futures were down very hard last night. If you are in the habit of selling on political news over this president's tweets, you have lost money. If you sold Friday and want to buy this morning because the ...
Amgen (NASDAQ: AMGN ) has agreed to acquire global rights to Celgene's (NASDAQ: CELG ) psoriasis med Otezla (apremilast) for $13.4B in cash. Bristol-Myers Squibb (NYSE: BMY ) is divesting the PDE4 inhibitor in order to receive regulatory sign-off on its merger with Celgene. The transaction...
THOUSAND OAKS, Calif. , Aug. 26, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE: BMY) to acquire worl...
Cancer treatment is one of the hottest areas of healthcare investing these days, with personalized medicine like genetic therapies providing new promises of treatment and potential cures. Still, despite the progress that researchers have made, there are still plenty of false starts and treatme...
Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG) claimed similar market caps earlier this year. That's not the case now, though. In March, Biogen announced that it was halting late-stage clinical studies for its once-promising Alzheimer's disease drug, aducanumab . The biotech's sh...
NetworkNewsWire Editorial Coverage : Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on investment. Genprex Inc. (NASDAQ: GNPX) ( GNPX Profi...
CELG stock is currently on a good run of good news in 2019 after a few years of bad news from Celgene Corporation (NASDAQ:CELG). In May, the company secured US Food and Drug Administration approval for a combination of Rituxan and Revlimid, which is a second-line follicular lymphoma and...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...